HOME >> MEDICINE >> NEWS
Chest x-rays not effective in determining when TB acquired

There is little correlation between the appearance of tuberculosis on chest x-rays and how recently the disease was acquired, according to a study in the June 8 issue of JAMA, a theme issue on tuberculosis.

Co-author Neil W. Schluger, M.D., of Columbia University, New York, presented the findings of the study at a JAMA media briefing on tuberculosis at the National Press Club.

Traditionally, active tuberculosis (TB) disease has been classified as either primary or secondary, reflecting the time between initial infection with Mycobacterium tuberculosis (MTB) and the onset of clinical disease, according to background information in the article. That interval can range over many years. Primary and secondary TB are also thought to have different characteristic radiographic (x-ray) and clinical features, though these clinical observations have been based on studies conducted before the availability of molecular fingerprinting techniques for TB. Molecular (DNA) fingerprinting, also known as restriction fragment length polymorphism (RFLP) analysis is a method for comparing strains of MTB from individual patients on a genetic basis. These techniques allow comparison of patients who have recently acquired tuberculosis to those whose tuberculosis was acquired long ago.

The researchers in this study used molecular fingerprinting and conventional epidemiology to test whether recently transmitted cases have radiographic features distinct from distantly acquired infection and secondly, whether the atypical features of the radiograph in HIV-associated TB are due to recent infection or are manifestations of altered immunity in the reactivation of latent infection. The study included 546 patients treated at a New York City medical center between 1990 and 1999. Eligible patients had to have had at least 1 positive respiratory culture for Mycobacterium tuberculosis and available radiographic data.

The researchers found that in " clinically well-de
'"/>

Contact: Neil W. Schluger, M.D.
212-305-4904
JAMA and Archives Journals
7-Jun-2005


Page: 1 2

Related medicine news :

1. News briefs from the journal Chest, August 2007
2. News briefs from the journal Chest, June 2007
3. News briefs from the journal Chest, March 2007
4. Newsbriefs from the journal Chest, December 2006
5. Newsbriefs from the journal Chest, November 2006
6. Newsbriefs from the journal Chest: October 2006
7. Newsbriefs from the journal Chest, August 2006
8. Newsbriefs from the journal Chest, May 2006
9. Newsbriefs from the journal Chest, April 2006
10. Newsbriefs from the journal Chest, March 2006
11. News briefs from the journal Chest, December 2005

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Chest rays not effective determining when acquired

(Date:5/21/2013)... Boca Raton, Fla. (PRWEB) May 21, 2013 ... TV program distributed on cable networks and cable channels ... of new episodes on its YouTube channel. The producers ... profiles of companies in the shipping industry, the manufacturing ... program highlights pioneering medical facilities and medical practitioners in ...
(Date:5/21/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... relationships. With the help of Texas Counseling’s Sexuality ... of communication, and the development of healthier habits ... group workshops available for both couples and individuals ... couples enhance their relationships and learn skills to ...
(Date:5/21/2013)... Brazilian funding agency for scientific and technological research So ... So Paulo, announced an investment estimated in US$ 680 ... (RIDCs) for a period of up to eleven years, ... 7. , Funding for the 17 RIDCs will ... faculty, technicians, support personnel, and infrastructure). Host institutions will ...
(Date:5/21/2013)... Go Classy Tours, the oldest and ... redesigned their website featuring N Resort in Jamaica ... bars and dining. The website, which has always featured ... guest reviews, will now have a broader range of ... on culinary local recipes, flora and fauna, featured pictures ...
(Date:5/21/2013)... va (PRWEB) May 21, 2013 ... critical technology and management consulting solutions to the ... of Business Development. In the newly created ... leading all aspects of the firm’s business development ... and proposal management functions, and leading strategies to ...
Breaking Medicine News(10 mins):Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Research at the cutting edge of knowledge 2Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2
(Date:5/21/2013)... NEW YORK , May 21, 2013 ... market research report is available in its ... Global Markets and Technologies for Optical Coherence ...   STUDY OBJECTIVES ... conducting this study is to offer synopsis ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... U.S. spending on specialty prescription drugs — ... cancer, multiple sclerosis and rheumatoid arthritis — is projected ... according to a forecast released today by Express Scripts ... "As we see what,s on the ... act so they can continue to offer an affordable ...
Breaking Medicine Technology:Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5
Cached News: